Literature DB >> 24752060

Reply to M.C. Chamberlain.

Mark R Gilbert1, James Dignam2, Stephanie Pugh2, Terri S Armstrong3, Jeffrey S Wefel4, Ken Aldape4, Roger Stupp5, Monika Hegi6, Minhee Won2, Walter J Curran7, Minesh P Mehta8.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24752060      PMCID： PMC4026583          DOI： 10.1200/JCO.2013.54.9717

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

2.  Lessons learned from Radiation Therapy Oncology Group 0525 trial.

Authors:  Marc C Chamberlain
Journal:  J Clin Oncol       Date:  2014-04-21       Impact factor: 44.544

3.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

4.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

Authors:  Antje Wick; Jörg Felsberg; Joachim P Steinbach; Ulrich Herrlinger; Michael Platten; Britta Blaschke; Richard Meyermann; Guido Reifenberger; Michael Weller; Wolfgang Wick
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

6.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Authors:  Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

7.  Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.

Authors:  A Tosoni; E Franceschi; M Ermani; R Bertorelle; L Bonaldi; V Blatt; Alba A Brandes
Journal:  J Neurooncol       Date:  2008-04-23       Impact factor: 4.130

8.  Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.

Authors:  James R Perry; Philippe Rizek; Rosemary Cashman; Meredith Morrison; Tara Morrison
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

9.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Authors:  Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller
Journal:  Lancet Oncol       Date:  2012-05-10       Impact factor: 41.316

10.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Authors:  E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.